CAMPBELL, Calif., Sept. 11, 2026 (GLOBE NEWSWIRE) — Arteris, Inc. (Nasdaq: AIP), a leading technology provider for accelerating semiconductor creation in the AI era, today announced that the company’s board of directors has granted equity awards to Saurabh Sinha, the company’s Chief Financial Officer, as inducement awards material to Mr. Sinha’s acceptance of employment with the company under the company’s 2022 Employment Inducement Incentive Plan. The grants were made in accordance with Nasdaq Listing Rule 5635(c)(4).

The awards consist of (i) restricted stock units (RSUs) with a target grant value of $3,700,000, covering 142,835 shares of the company’s common stock, and (ii) performance stock units (PSUs) with a target grant value of $1,000,000, covering a target of 38,604 shares of the company’s common stock. In each case, the number of shares subject to the award was determined by dividing the target grant value by the 30-day trailing average price of the company’s common stock immediately prior to the effective date of the grant.

The RSUs vest as to 25% of the underlying shares on the first anniversary of the grant date, with the remainder vesting pro rata by day on the first day of each of the 12 consecutive fiscal quarters thereafter, aligned with fiscal quarterly vesting commencing January 1, 2028, in each case subject to Mr. Sinha’s continued service with the company through the applicable vesting date.

The PSUs vest upon satisfaction of two performance conditions: (i) the company achieving annual trailing four quarters’ publicly reported revenue of $200,000,000 or greater at any time on or before December 31, 2030; and subsequently (ii) the company’s common stock achieving a closing share price of $65 or greater, calculated as an average over a trading period of 15 trading days, at any time on or before December 31, 2031, in each case subject to Mr. Sinha’s continued service with the company through the applicable vesting date. In the event a change in control of the company occurs prior to the date the performance goals have been achieved, the PSUs shall not vest, and shall be forfeited for no consideration, effective upon the consummation of the change in control.

Mr. Sinha has entered into the company’s Form of Executive Change in Control Severance Agreement, which provides for full accelerated vesting of any unvested equity awards (except for any performance awards, including the PSUs, which are governed by the terms of the applicable award agreement) in the event of Mr. Sinha’s termination without cause or resignation for good reason during the period commencing three months prior to a change in control of the company and ending on the 12-month anniversary following such change in control.

The effective grant date of the awards was September 8, 2026, Mr. Sinha’s start date with the company, and the awards were approved by the company’s board of directors.

About Arteris

Arteris is a leading provider of semiconductor technology that accelerates the creation of high-performance, power-efficient silicon with built-in safety, reliability, and security. Innovative Arteris products are designed to optimize data movement and help ease complexity in the modern AI era with network-on-chip (NoC) interconnect intellectual property (IP), system-on-chip (SoC) software for integration automation and hardware security assurance. All are used by the world’s top technology companies to improve overall performance and engineering productivity, reduce risk, lower costs, and bring cutting-edge designs to market faster. Learn more at arteris.com.

© 2004–2026 Arteris, Inc. All rights reserved worldwide. Arteris, Arteris IP, the Arteris IP logo, and the other Arteris marks found at https://www.arteris.com/trademarks are trademarks or registered trademarks of Arteris, Inc. or its subsidiaries. All other trademarks are the property of their respective owners.

Investor Contacts:
Arteris
Saurabh Sinha
Saurabh.Sinha@arteris.com

Sapphire Investor Relations, LLC
Erica Mannion and Michael Funari
+1 617 542 6180
IR@arteris.com

Media Contact:
Gina Jacobs
Arteris
+1 408 560 3044
newsroom@arteris.com

This press release was published by a CLEAR® Verified individual.

The Class A ordinary shares will trade under the symbol “RNAQ” and the warrants under the symbol “RNAQW” on The Nasdaq Capital Market, while units that are not separated will continue to trade under the symbol “RNAQU.”

NEW YORK, NY, Sept. 11, 2026 (GLOBE NEWSWIRE) — Rainier Acquisition Corporation (Nasdaq: RNAQU) (the “Company”) announced today that, commencing September 14, 2026, holders of the units sold in its initial public offering (the “Units”) may elect to separately trade the Class A ordinary shares and warrants included in the Units. Each Unit consists of one Class A ordinary share and one-quarter of one redeemable warrant. No fractional warrants will be issued upon separation of the Units, and only whole warrants will trade. Each whole warrant entitles the holder thereof to purchase one Class A ordinary share at a price of $11.50 per share, subject to certain adjustments. Only whole warrants are exercisable.

The Class A ordinary shares and warrants that are separated will begin trading on The Nasdaq Capital Market (“Nasdaq”) on September 15, 2026 under the symbols “RNAQ” and “RNAQW,” respectively. Units that are not separated will continue to trade on Nasdaq under the symbol “RNAQU.” Holders of Units will need to have their brokers contact Continental Stock Transfer & Trust Company, the Company’s transfer agent, in order to separate the Units into Class A ordinary shares and warrants.

The Units began trading on Nasdaq on August 27, 2026. The Company’s initial public offering, including the full exercise of the underwriter’s over-allotment option, totaled 8,625,000 Units and generated gross proceeds of $86,250,000, before underwriting discounts and offering expenses, and an aggregate of $86,250,000 ($10.00 per Unit) was placed in the Company’s trust account. Chardan Capital Markets LLC (“Chardan”) acted as the sole book-running manager for the offering.

About Rainier Acquisition Corporation

Rainier Acquisition Corporation (Nasdaq: RNAQU, RNAQ, RNAQW) is a special purpose acquisition company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The Company intends to focus its search on the global life sciences industries, including therapeutics, diagnostics, genomics, precision medicine, life science tools, research services, biomanufacturing, and related subsectors, although its efforts to identify a prospective target business will not be limited to any particular industry or geographical region. The Company’s management team is led by Gbola Amusa, MD, CFA, Chief Executive Officer, and Guy Barudin, Chief Financial Officer. The Company’s filings with the U.S. Securities and Exchange Commission (the “SEC”) are available at www.sec.gov.

The offering was made only by means of a prospectus. Copies of the prospectus may be obtained from Chardan, 1 Pennsylvania Plaza, Suite 4800, New York, New York 10119, or by email at prospectus@chardan.com.

A registration statement relating to these securities was declared effective by the SEC on August 26, 2026. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any State or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such State or jurisdiction.

Cautionary Note Concerning Forward-Looking Statements

This press release includes forward-looking statements that involve risks and uncertainties, including with respect to the timing of separate trading and the Company’s search for an initial business combination. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. The Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company’s registration statement and related prospectus for the Company’s initial public offering filed with the SEC. Copies of these documents are available on the SEC’s website, at www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

Contact:
Rainier Acquisition Corporation
Gbola Amusa, MD, CFA, Chief Executive Officer
1 Pennsylvania Plaza, Suite 4800
New York, NY 10119
Tel.: (646) 465-9000
gamusa@rainier-acq.com

ROCKVILLE, Md., Sept. 11, 2026 (GLOBE NEWSWIRE) — MaxCyte, Inc. (Nasdaq: MXCT), a leading cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, reported today that the Compensation Committee of the Board of Directors of MaxCyte granted inducement awards in the form of stock options to purchase an aggregate of 220,000 shares of MaxCyte’s common stock and a service-based restricted stock unit (“RSU”) award with respect to 110,000 shares of MaxCyte’s common stock to Sidharth Kapileshwar, in connection with his commencement of employment as Senior Vice-President, Chief Corporate Development Officer at MaxCyte. The awards were granted under the MaxCyte, Inc. 2026 Inducement Plan (the “Plan”) with a grant date of August 31, 2026 as an inducement material to entering into employment with MaxCyte, in accordance with Nasdaq Listing Rule 5635(c)(4).

The stock options are scheduled to vest over four years, with 25% vesting on the first anniversary of the grant date and the remaining shares vesting monthly over the 36-month period thereafter, subject to the employee’s continuous service with MaxCyte through the applicable vesting dates. The stock options have a ten-year term and an exercise price of $1.29, the closing price of MaxCyte’s common stock as reported by Nasdaq on August 31, 2026.

The RSUs are scheduled to vest over four years, with 25% vesting on the first anniversary of August 31, 2026 and the remainder vesting in three equal annual installments thereafter, subject to the employee’s continuous service with MaxCyte through the applicable vesting dates.

MaxCyte is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4).

About MaxCyte

At MaxCyte®, we are committed to building better cells together. As a leading cell-engineering company, we are driving the discovery, development and commercialization of next-generation cell therapies. Our best-in-class Flow Electroporation® technology and SeQure™ gene editing risk assessment services enable high-performance cell engineering and rigorous evaluation of editing outcomes, supporting confidence in therapeutic development. Supported by expert scientific, technical and regulatory guidance, our platform empowers researchers to engineer diverse cell types and payloads, accelerating the development of safe and effective treatments for human health. For more than 25 years, we’ve been advancing cell engineering, shaping the future of medicine. 

Learn more at maxcyte.com and follow us on LinkedIn and Bluesky.

MaxCyte Contacts:

US IR Adviser
Gilmartin Group
Erik Abdow
ir@maxcyte.com

Media Contact
Oak Street Communications
Kristen White
kristen@oakstreetcommunications.com
415.608.6060

IMPORTANT NOTICE – DISCLAIMER

Not for release or distribution or publication in whole or in part, directly or indirectly, in or into Australia, Canada, Japan or the Republic of South Africa. These materials do not contain or constitute an offer for sale or the solicitation of an offer to purchase securities in the United States, Australia, Canada, Japan or the Republic of South Africa.

The securities mentioned herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”), and may not be offered or sold in the United States or to U.S. persons absent such registration, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. No offering of securities is being made in the United States or to U.S. persons.

ATHENS, Greece, Sept. 11, 2026 (GLOBE NEWSWIRE) — “AXIA Ventures Group Ltd”, member of the Alpha Bank Group, acting as Lead Advisor and Joint Coordinator and Bookrunner and “National Bank of Greece S.A.”, acting as Co-Advisor and Joint Coordinator and Bookrunner, in connection with the Public Offering in Greece and the admission to parallel listing of all common, registered, voting shares of “Star Bulk Carriers Corp.” (the “Company”), for trading on the Main Market the Regulated Securities Market of Euronext Athens, following the completion of the Public Offering on Friday, 11 September 2026, hereby announce, in accordance with article 17(2) and article 21(2) of Regulation (EU) 2017/1129, that a total of 4,400,000 new, common, registered, voting shares of the Company were allocated (the “New Shares”), including the shares of the parallel offering to a limited group of persons, in accordance with decision no. 4/379/18.04.2006 of the Board of Directors of the Hellenic Capital Market Commission.

The final offering price of the Company’s New Shares was determined at €24.50 (US$ 28.40)1 per New Share and is the same for all investors, Qualified and Retail, who participated in the Public Offering and the Parallel Offering.

The total valid demand expressed in the context of the Public Offering amounted to 26,788,512 shares, at the final offering price of €24.50 (US$ 28.40)1 per New Share, i.e. a total value of €656.3 million, resulting in the Public Offering being oversubscribed by over 6 times.

Detailed information regarding the allocation of the New Shares offered through the Public Offering by investor category will be announced on Tuesday, 15 September 2026.

The New Shares have not been, and will not be, registered under the U.S. federal securities laws or the securities laws of any other jurisdiction, and the New Shares may not be offered or sold in the United States or to U.S. persons unless an exemption from the registration requirements of the Securities Act is available. The New Shares are being offered and sold to non-U.S. persons outside the United States in offshore transactions in reliance on Regulation S under the Securities Act.

Friday, 11 September 2026

Important Notice – Disclaimer

This announcement includes “forward-looking statements,” with respect to our expectations or beliefs concerning future events. Words such as, but not limited to, “believe,” “expect,” “anticipate,” “estimate,” “intend,” “plan,” “targets,” “projects,” “likely,” “would,” “will,” “could,” “should,” “may,” “forecasts,” “potential,” “continue,” “possible” and similar expressions or phrases may identify forward-looking statements.

All forward-looking statements involve risks and uncertainties. The occurrence of the events described depend on many factors, some or all of which are not predictable or within our control. Important factors that, in our view, could cause actual results to differ materially from those discussed in the forward-looking statements include, but are not limited to, market conditions, disruptions to the mechanics required to operate cross-border trading, disruptions to trading on Euronext Athens, and other technical impediments to the commencement of trading. All future written and verbal forward-looking statements attributable to us or any person acting on our behalf are expressly qualified in their entirety by the cautionary statements contained or referred to in this section. We undertake no obligation, and specifically decline any obligation, except as required by law, to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


1 The Offering Price has been converted into U.S. dollars based on the Euro/U.S. dollar (EUR/USD) exchange rate as of 11.09.2026 (€1 = 1.1592 USD). (Source: “European Central Bank” at Greek market close).

Contacts

Company: Investor Relations / Financial Media:
Simos Spyrou, Christos Begleris Nicolas Bornozis
Co ‐ Chief Financial Officers President
Star Bulk Carriers Corp. Capital Link, Inc.
c/o Star Bulk Management Inc. 230 Park Avenue, Suite 1540
40 Ag. Konstantinou Av. New York, NY 10169
Maroussi 15124 Tel. (212) 661‐7566
Athens, Greece E‐mail: starbulk@capitallink.com
Email: info@starbulk.com www.capitallink.com
www.starbulk.com

  • Holds 515,544 BNB tokens with a fair value of approximately $302.3 million at July 31, 2026
  • Repurchased 1,434,112 shares of common stock for $3.8 million at an average price of $2.63 per share
  • Reports first quarter fiscal 2027 net loss of $11.4 million, or $(0.22) per diluted share

LOUISVILLE, CO, Sept. 11, 2026 (GLOBE NEWSWIRE) — CEA Industries Inc. (Nasdaq: BNC) (“CEA Industries,” “BNC,” or the “Company”), a growth-oriented company focused on managing the world’s largest corporate treasury of BNB, today announced its financial results for the first quarter of fiscal 2027, ended July 31, 2026.

First Quarter Fiscal 2027 Financial Highlights

  • Net Loss: Reported a net loss of $11.4 million, or $(0.22) per basic and diluted share. Results were driven primarily by a $15.3 million unrealized loss on digital assets, of which $15.0 million related to BNB, partially offset by a $10.0 million non-cash gain on the change in fair value of warrant liabilities.
  • Digital Asset Holdings: At July 31, 2026, the Company held 515,544 BNB tokens (471,346 unrestricted and 44,198 pledged as loan collateral) with a fair value of $302.3 million, unchanged in token count from April 30, 2026. Including BTC and USDT positions, total digital assets had a fair value of $304.5 million and represented 93.1% of total assets.
  • Treasury Yield: Generated $0.3 million of Airdrop income within the Binance ecosystem, reflecting a continued moderation in Airdrop, Launchpool and HODLer program activity across the ecosystem.
  • Revenue and Gross Profit: Revenue from the Retail and Industry segment was $7.2 million, compared to $7.5 million in the combined prior-year quarter, a decrease of 4.6% driven primarily by the discontinuance of a product line at Fat Panda. Gross profit was $2.0 million, compared to $2.3 million in the combined prior-year period corresponding to the revenue decline.
  • Operating Expenses: Total operating expenses were $23.2 million, including the $15.3 million unrealized loss on digital assets described above, $1.4 million of shareholder advisory expenses related to the activism campaign resolved in June 2026 and $1.1 million of management fees under the Asset Management Agreement. The Company does not expect to incur material additional shareholder advisory costs related to the resolved activism campaign.
  • Liquidity: Ended the quarter with $7.1 million of cash and cash equivalents, up from $3.1 million at April 30, 2026. The Company drew $15.0 million of USDC under its master loan facility, secured by 44,198 BNB valued at $25.9 million at quarter end, without liquidating core treasury assets. Total debt outstanding was $16.8 million. The Company was in compliance with all debt covenants at July 31, 2026.
  • Share Repurchases: During the quarter, the Company repurchased and cancelled 1,434,112 shares of common stock at an average price of $2.63 per share for a total of $3.8 million under its $250 million share repurchase program authorized in September 2025.
  • Balance Sheet: Total assets were $327.2 million and total shareholders’ equity was $289.4 million at July 31, 2026. Shares of common stock outstanding were 41,173,850, down from 42,607,962 at April 30, 2026 resulting from the aforementioned share repurchases.

Corporate Governance and Operational Highlights

  • Cooperation Agreement with YZILabs: On June 23, 2026, the Company entered into a cooperation agreement with YZILabs resolving the consent solicitation and related activism campaign commenced in November 2025. YZILabs terminated its consent solicitation and withdrew its related demands and is subject to standstill, voting and mutual non-disparagement covenants. The Board was increased to six directors with the appointments of Ling “Ella” Zhang, Alex Odagiu and Matthew Roszak, and the parties agreed to appoint a seventh mutually agreeable director, which remains pending.
  • Board and Leadership Evolution: Carly E. Howard was named Chair of the Board effective May 6, 2026. Alex Odagiu has served as Interim President, reporting directly to the Board, since June 23, 2026. On July 22, 2026, David Namdar concluded his service as Chief Executive Officer in accordance with his March 2026 transition agreement, and the Board appointed William B. Miller, Chief Financial Officer, to serve additionally as Interim Principal Executive Officer without additional compensation. The Board formed a chief executive officer search committee on June 29, 2026 and its search is ongoing.
  • Nasdaq Listing Compliance: On August 5, 2026, Nasdaq notified the Company that it had regained compliance with Listing Rule 5620(a) following the July 22, 2026 special meeting and that the matter is closed.
  • Asset Management Agreement (AMA) Litigation: The Company filed a complaint on May 22, 2026 in the U.S. District Court for the District of Delaware, seeking to void the AMA from inception and, in the alternative, a declaration that the agreement’s liquidated damages provision is an unenforceable penalty, remains pending. The Asset Manager moved to dismiss on July 28, 2026 and the Company filed its opposition on August 14, 2026. The Company has not terminated the AMA and no amount is presently due under that provision.
  • Retail Operations: At July 31, 2026, Fat Panda operated 34 retail locations across Central Canada, comprised of 30 Fat Panda branded stores and 4 Electric Fog branded outlets, together with an e-commerce platform and in-house premium e-liquid manufacturing.

Business Outlook

CEA Industries remains committed to the disciplined execution of its BNB digital asset treasury strategy. With the shareholder activism campaign resolved, the Board substantially reconstituted and Nasdaq annual meeting deficiency restored, the Company’s near-term priorities are focused on driving operational and strategic execution and resolving the pending Asset Management Agreement litigation.

The Company intends to continue holding its position as the world’s largest corporate BNB treasury and, when capital allows, may add to its BNB holdings. CEA Industries also plans to continue to evaluate additional treasury management opportunities within the BNB ecosystem, while maintaining a disciplined approach to liquidity, risk management and shareholder value creation.

About CEA Industries Inc.

CEA Industries Inc. (Nasdaq: BNC) is a growth-oriented company that focuses on building category-leading businesses in consumer markets, including building and managing the world’s largest corporate treasury of BNB.

Forward-Looking Statements

This press release contains statements that constitute “forward-looking statements” within the meaning of the U.S. federal securities laws, which reflect our current views with respect to, among other things, our operations and financial performance. You can identify these forward-looking statements by the use of words such as “outlook,” “believe,” “expect,” “potential,” “continue,” “may,” “should,” “seek,” “approximately,” “predict,” “intend,” “will,” “plan,” “project,” “target,” “estimate,” “anticipate,” “conviction,” the negative version of these words, other comparable words or other statements that do not relate strictly to historical or factual matters. By their nature, forward-looking statements speak only as of the date they are made, are not statements of historical fact or guarantees of future performance and are subject to risks, uncertainties, assumptions or changes in circumstances that are difficult to predict or quantify. BNC’s expectations, beliefs and projections are expressed in good faith and BNC believes there is a reasonable basis for them. However, there can be no assurance that BNC’s expectations, beliefs and projections will result or be achieved and actual results may vary materially from what is expressed in or indicated by the forward-looking statements.

The statements in this press release that are not purely historical are forward-looking statements which involve risks and uncertainties. Examples of forward-looking statements include, but are not limited to, statements regarding the Company’s execution of its BNB digital asset treasury strategy, driving operational and strategic execution and resolving the pending Asset Management Agreement litigation, the Company’s position as the world’s largest corporate BNB treasury, the Company’s BNB holdings, treasury management opportunities within the BNB ecosystem, the Company’s expectations with respect to shareholder advisory costs, the Company’s director search, the Company’s CEO search, the Company’s financial condition and liquidity outlook, the Company’s future financial results, share repurchases, strategy, plans, objectives, expectations (financial or otherwise) and growth potential, and the Company’s ability to create shareholder value. BNC wishes to caution readers that these forward-looking statements may be affected by the risks and uncertainties in BNC’s business, as well as other important factors that may have affected and could in the future affect BNC’s actual results and could cause BNC’s actual results for subsequent periods to differ materially from those expressed in any forward-looking statement made by or on behalf of BNC. In evaluating these forward-looking statements, readers should consider various risk factors, which include, but are not limited to: volatility in the market price of BNB and other digital assets; the concentration of BNC’s holdings in BNB and of its custody arrangements within the Binance ecosystem; collateral maintenance and repayment obligations under BNC’s master loan facility; the outcome of the AMA litigation, BNC’s non-payment of accrued management fees, and the enforceability of the AMA’s liquidated damages provision; BNC’s ability to appoint a permanent chief executive officer and an additional independent director within the deadlines under the Cooperation Agreement; the previously disclosed material weakness in BNC’s internal control over financial reporting; BNC’s continued compliance with Nasdaq listing requirements; BNC’s ability to finance its current business and proposed future business, including the ability to finance the continued acquisition of BNB; evolving laws, regulations and accounting guidance applicable to digital assets; the future value and adoption of BNB; shareholder activism; outcome of the Company’s director and CEO searches; and execution of the Company’s BNB digital asset treasury strategy.

Forward-looking statements are subject to numerous conditions and risks, many of which are beyond BNC’s control. In addition, these forward-looking statements and the information in this press release are qualified in their entirety by cautionary statements and risk factor disclosures contained in BNC’s filings with the SEC, including BNC’s most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q and BNC’s subsequent filings with the SEC, as each may be amended or supplemented from time to time. Copies of BNC’s filings with the SEC are available on the SEC’s website at www.sec.gov. BNC undertakes no obligation to update these forward-looking statements for revisions or changes after the date of this press release, except as required by law.

CEA Industries Media Inquiries:
bnc@cw8.co

CEA Industries Investor Relations:
james@haydenir.com

INDIANAPOLIS, Sept. 11, 2026 (GLOBE NEWSWIRE) — Kite Realty Group (NYSE: KRG) announced today that it will present at the BofA Securities 2026 Global Real Estate Conference. The presentation information is as follows:

Event: Kite Realty Group Management Presentation
When: September 15, 2026, at 3:00 p.m. ET
Live Webcast: Kite Realty Group BofA Securities 2026 Global Real Estate Conference
Investor Presentation: KRG Q2 2026 Investor Update

A replay of the webcast will be available at kiterealty.com following the completion of the conference.

About Kite Realty Group

Kite Realty Group (NYSE: KRG) is a real estate investment trust (REIT) that owns and operates a high-quality portfolio of open-air shopping centers and mixed-use destinations. The Company’s portfolio is concentrated in high-growth Sun Belt and select strategic gateway markets. Publicly listed since 2004, KRG brings more than six decades of experience in developing, operating, and investing in real estate, using a disciplined, hands-on approach to enhance portfolio quality and maximize long-term value for all stakeholders. As of June 30, 2026, the Company owned interests in 165 U.S. open-air shopping centers and mixed-use assets, comprising approximately 26.4 million square feet of gross leasable space. For more information, please visit kiterealty.com.

Connect with KRG: LinkedIn | X | Instagram | Facebook

Contact Information: Kite Realty Group
Cooper Clark
VP, Capital Markets & Investor Relations
773.980.0213
coclark@kiterealty.com

SAN MATEO, Calif., Sept. 11, 2026 (GLOBE NEWSWIRE) — Oportun Financial Corporation (“Oportun”, or the “Company”) today announced that, on September 10, 2026, in accordance with the offer letter agreement with Sean Rowles, the Company’s Chief Risk Officer, previously announced by the Company on June 16, 2026, it granted a long-term new hire equity award consisting of 382,653 restricted stock units representing the right to receive an equivalent number of shares of the Company’s common stock (“RSUs”) and 127,551 performance-vesting restricted stock units representing the right to receive an equivalent number of shares of the Company’s common stock at target (“PSUs”) to Mr. Rowles, effective on September 10, 2026. The RSUs and PSUs were an inducement material to Mr. Rowles entering into employment with the Company and granted under and subject to the terms of the Company’s Amended and Restated 2021 Inducement Equity Incentive Plan and applicable award agreements. The RSUs will vest as to one-third of the award on the one-year anniversary of the grant date and as to the remaining two-thirds of the award in eight substantially equal quarterly installments, such that the RSUs will be fully vested on the third anniversary of the grant date. The PSUs are eligible to vest after the end of the three-year performance period, based on a combination of performance goals and vesting terms. The vesting of the RSUs and PSUs is generally subject to Mr. Rowles remaining in continuous service with the Company through the relevant vesting dates. Mr. Rowles’s offer letter agreement was filed as Exhibit 10.2 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on June 18, 2026. The Amended and Restated 2021 Inducement Equity Incentive Plan and the forms of RSU and PSU award agreements are filed as exhibits to the Company’s Quarterly Report on Form 10-Q filed with the SEC on May 8, 2026.

About Oportun

Oportun (Nasdaq: OPRT) is a mission-driven financial services company that puts its members’ financial goals within reach. With intelligent borrowing, savings, and budgeting capabilities, Oportun empowers members with the confidence to build a better financial future. Since inception, Oportun has provided more than $22.7 billion in responsible and affordable credit, saved its members more than $2.5 billion in interest and fees, and helped its members set aside an average of more than $1,800 annually.

For more information, visit Oportun.com.

Investor Contact
Dorian Hare
(650) 590-4323
ir@oportun.com

Media Contact
Michael Azzano
Cosmo PR for Oportun
(415) 596-1978
michael@cosmo-pr.com

Antwerp, Belgium, September 11, 2026 – Agomab Therapeutics NV (Nasdaq: AGMB) (“Agomab” or the “Company”), a clinical-stage biopharmaceutical company focused on fibro-inflammatory diseases, today announced that shareholders approved all resolutions submitted for consideration at the Company’s Special and Extraordinary General Shareholders’ Meeting held on September 11, 2026. The approved resolutions included the appointments of Marino Garcia and Naimish Patel, M.D. as non-executive members of the Company’s Board of Directors and the proposed consolidation and split adjustment of outstanding pre-Initial Public Offering (IPO) warrants.

“We are grateful for the support of our shareholders and excited to formally welcome Marino and Naimish to our Board,” said Tim Knotnerus, Chief Executive Officer of Agomab. “Both bring exceptional and complementary experience that will be highly valuable as we continue to advance our portfolio of potential disease-modifying therapies for fibro-inflammatory diseases. We look forward to benefiting from their perspectives as we work to create meaningful value for patients and shareholders alike.”

Marino Garcia commented, “I am honored to join Agomab’s Board at such an exciting stage in the Company’s development. Agomab has built a compelling pipeline targeting fibro-inflammatory diseases with significant unmet need, supported by a talented leadership team and strong scientific foundation. I look forward to working closely with the Board and management team to help advance the Company’s strategy and long-term vision.”

Naimish Patel, M.D., added, “I am delighted to join Agomab’s Board and contribute to the Company’s mission of developing innovative therapies for patients with fibro-inflammatory diseases. The combination of strong science, clear clinical focus and commitment to addressing significant unmet medical needs creates an exciting opportunity. I look forward to bringing my experience in translational medicine and clinical development to support Agomab’s continued progress.”

The Company also announced that shareholders approved the proposed consolidation and split adjustment of outstanding pre-IPO warrants, aligning such warrants with the share split implemented in connection with Agomab’s IPO in February 2026.

The materials relating to the Special and Extraordinary General Shareholders’ Meeting, including the biographies of the newly appointed Board members, are available on the Company’s website.

About Agomab
Agomab is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for fibro-inflammatory diseases with high unmet medical need. Agomab’s product candidates are designed to target established, potent pathways and utilize organ-restricted approaches, with the aim of increasing efficacy while minimizing safety liabilities. Fostering a culture of excellence, Agomab’s mission is to pioneer therapeutics that aim to resolve fibro-inflammation and restore organ function to enable people with these disorders to live fuller and healthier lives.

Cautionary Note regarding Forward-Looking Statements
This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “continue,” “anticipate,” “believe,” “could,” “estimate,” “expect,” “goal,” “intend,” “look forward to,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” and similar expressions. Such forward-looking statements include, but are not limited to, express and implied statements regarding the anticipated contributions of Marino Garcia and Naimish Patel, M.D. to the Company’s Board of Directors, the Company’s strategy and long-term vision, and the continued advancement of our portfolio of potential disease-modifying therapies for fibro-inflammatory diseases. Forward-looking statements are based on management’s beliefs and assumptions and on information available to management only as of the date of this press release. Our actual results could differ materially from those expressed or implied by these forward-looking statements for many reasons, including, without limitation, the risks, uncertainties and other factors in our filings made with the Securities and Exchange Commission, including certain sections of our annual report filed on Form 20-F. These risks and uncertainties include, among others, the cost, timing and results of preclinical studies and clinical trials and other development activities by us and our collaborative partners; the likelihood of our preclinical and clinical programs being initiated and executed on timelines provided and reliance on our contract research organizations; our reliance on contract manufacturers to supply materials for research and development and the risk of supply interruption from a contract manufacturer; the potential for future data to alter initial and preliminary results of early-stage clinical trials; the unpredictability of the duration and results of the regulatory review of applications or clearances that are necessary to advance our clinical programs; the ability to secure, maintain and realize the intended benefits of collaborations with partners; the possible impairment of, inability to obtain, and costs to obtain intellectual property rights; possible safety or efficacy concerns that could emerge as new data are generated in research and development; general business, operational, financial and accounting risks, and risks related to litigation and disputes with third parties; and risks related to macroeconomic conditions and market volatility resulting from global economic developments, geopolitical instability and conflicts. Given these risks, uncertainties, and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law.

Contacts
Investors
Sofie Van Gijsel
VP of Investor Relations
E-Mail: sofie.vangijsel@agomab.com
Phone: +1 781 296 1143
        
Media
Gretchen Schweitzer
Trophic Communications
E-Mail: agomab@trophic.eu 
Phone: +49 172 861 8540

EMERYVILLE, Calif., Sept. 11, 2026 (GLOBE NEWSWIRE) — 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that on September 8, 2026, the compensation committee of the Company’s board of directors granted seven new non-executive employees 96,000 Restricted Stock Units (RSUs). The RSUs were granted pursuant to the Company’s 2025 Employment Inducement Award Plan, as amended, under Rule 5635(c)(4) of The Nasdaq Global Market for equity grants to induce new employees to enter into employment with the Company.

About 4DMT

4DMT is a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. The Company’s lead product candidate 4D-150 is designed to be a backbone therapy forming the foundation of treatment of blinding retinal vascular diseases by providing multi-year sustained delivery of anti-VEGF biologics (aflibercept and anti-VEGF-C) with a single intravitreal injection, which substantially reduces the treatment burden associated with current bolus injections. The Company’s lead indication for 4D-150 is wet age-related macular degeneration, which is currently in Phase 3 development, and second indication is diabetic macular edema. The Company’s second product candidate is 4D-710, which is the first known genetic medicine to demonstrate successful delivery and expression of the CFTR transgene in the lungs of people with cystic fibrosis after aerosol delivery. 4D Molecular Therapeutics™, 4DMT™, Therapeutic Vector Evolution™, Backbone 4 Retina™ and the 4DMT logo are trademarks of 4DMT.  

All of the Company’s product candidates are in clinical or preclinical development and have not yet been approved for marketing by the U.S. Food and Drug Administration or any other regulatory authority. No representation is made as to the safety or effectiveness of the Company’s product candidates for the therapeutic uses for which they are being studied.

Learn more at www.4DMT.com and follow us on LinkedIn. 

CONTACT: Contacts:

Media:

Jenn Gordon
dna Communications
Media@4DMT.com

Investors:

Julian Pei
Head of Investor Relations and Strategic Finance
Investor.Relations@4DMT.com

HOUSTON, Sept. 11, 2026 (GLOBE NEWSWIRE) — Impact BioMedical Inc. (the “Company”) today announced that the Company’s Board of Directors has approved a 1 for 12.62 reverse stock split of the Company’s issued and outstanding common stock, par value $0.001 per share (the “Common Stock“). The reverse stock split will become effective at 12:01 a.m., Eastern Time, on September 23, 2026. Starting with the opening of trading on that date, the Company’s Common Stock will continue to trade on the NYSE American Exchange under the ticker symbol “IBO” and will trade under a new CUSIP number to be assigned in connection with the reverse stock split.

On December 30, 2025, the Company’s stockholders approved a second reverse stock split of the Company’s Common Stock at a ratio of not less than 1-for-12.48 and not more than 1-for-50 to be implemented at the discretion of the Chief Executive Officer. The Reverse Stock Split is intended to support the Company’s efforts in connection with the proposed business-combination transaction and its continued-listing objectives. The Reverse Stock Split does not assure that the Company will satisfy applicable NYSE American continued-listing standards, obtain approval of any applicable listing application, or complete the proposed transaction.

The merger of Impact BioMedical Inc. and Zoar Ltd, upon approval, will result in a new company with manufacturing and clinical development expertise across a broad spectrum of active pharmaceutical ingredients (API’s) and intermediates for life-saving drugs worldwide, with immediate focus on emerging markets. It will also include significant intellectual property with potential in human health and wellness markets.

( Read the original merger announcement here.).  

Upon completion of the proposed merger, Impact stockholders are expected to receive one (1) share of Zoar Ltd. for every four (4) shares of Impact Common Stock held immediately prior to the effective time of the merger, after giving effect to the Reverse Stock Split.

The reverse stock split will combine every 12.62 shares of the Company’s issued and outstanding Common Stock into one (1) new share of Common Stock. No fractional shares will be issued in connection with the Reverse Stock Split. Stockholders who would otherwise be entitled to receive a fractional share will have their fractional share rounded up to the next whole share. Other than adjustments resulting from the treatment of fractional shares, the Reverse Stock Split will affect all stockholders uniformly and will not alter any stockholder’s percentage ownership interest in the Company.

Stockholders holding shares in book-entry form or through a bank, broker, or other nominee do not need to take any action. Impact BioMedical’s transfer agent, Equiniti Trust Company, LLC (“Equiniti”), will manage the exchange. Stockholders of record who hold physical certificates will receive a letter of transmittal from Equiniti with instructions for exchanging their shares. Unless a stockholder specifically requests new paper certificates (or holds restricted shares), new shares will be issued electronically in book-entry form.

Following the reverse stock split, the total number of shares of Common Stock outstanding is expected to decrease from approximately 107,821,231 to 8,543,679 subject to minor adjustments due to rounding. Corresponding proportional adjustments will also be made to:

  • Outstanding equity awards and related exercise prices
  • Shares available under equity incentive plans
  • Other relevant share-based agreements

The reverse stock split will not affect the total number of authorized shares, and all resulting shares will remain fully paid and non-assessable.

Additional information about the reverse stock split can be found in the Company’s definitive information statement filed with the Securities and Exchange Commission (the “SEC“) on December 30, 2025, which is available free of charge at the SEC’s website, www.sec.gov.

About Zoar Ltd.
Zoar Ltd. is a global pharmaceutical company focused on the development and manufacturing of active pharmaceutical ingredients, formulations, orphan drugs, and contract development and manufacturing services for pharmaceutical and biotechnology companies worldwide.

About IBO:
Impact BioMedical Inc. discovers, confirms, and patents unique science and technologies which can be developed into new offerings in biopharmaceuticals and consumer healthcare and wellness in collaboration with external partners through research, licensing, co-development, joint ventures, and other relationships.

Safe Harbor Disclosure:
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements are subject to risks and uncertainties that may cause actual results or events to differ materially from those projected. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date.

Investor Relations:
info@impactbiomedinc.com
www.impactbiomedinc.com

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.